Market Overview - U.S. stock futures increased on Monday, continuing Friday's gains, driven by optimism regarding a potential December rate cut suggested by New York Fed President John Williams [1] - The Dow Jones Industrial Average rose 0.44% to 46,448.27, the S&P 500 increased by 1.5% to 6,705.12, and the Nasdaq jumped 2.69% to 22,872.00 [1] Semiconductor Sector - The semiconductor sector experienced a boost as hopes for a December Fed rate cut lifted tech stocks, with supportive comments from Federal Reserve Governor Christopher Waller further fueling the rally [2] Broadcom Inc. - Broadcom's stock surged 11.10% to close at $377.96, reaching an intraday high of $382 and a low of $347.66, with a 52-week high of $386.48 and a low of $138.10; in after-hours trading, the stock rose 1.49% to $383.60 [1] Alphabet Inc. - Alphabet's Class C shares climbed 6.28% to close at $318.47, hitting a new 52-week high of $319.80, with a low of $142.66; after-hours trading saw a gain of 2.65% to $326.90 [3][4] - Alphabet's Class A shares ended the day 6.3% higher at $318.58, gaining 2.6% to $327 in extended trading [3] - The company is reportedly in talks with Meta and other cloud clients to supply Google's AI TPU chips, indicating increased competition with Nvidia; Alphabet shares rose about 2% after-hours while Nvidia slipped roughly 2% [4] SanDisk Corporation - SanDisk's stock rose 13.33% to $226.96, with a high of $228.18 and a low of $205.13; the stock's 52-week high is $284.76 and a low of $27.90, popping 7.29% to $243.50 in after-hours trading [5][6] - SanDisk was added to the S&P 500, replacing Interpublic Group after its acquisition by Omnicom, effective November 28; PTC Therapeutics will replace SanDisk in the S&P SmallCap 600 [6] - The company reported strong fourth-quarter results on November 6, beating revenue and EPS estimates for the eighth time in ten quarters [6] Novo Nordisk A/S - Novo Nordisk shares fell 5.58% to $44.97, with a high of $45.22 and a low of $43.08; the stock's 52-week high is $112.52 [7][8] - The company reported that its 2-year evoke and evoke+ trials did not show semaglutide to be superior to placebo in slowing Alzheimer's disease progression, despite improvements in biomarkers; the 1-year extension phase will be discontinued [8] Zoom Communications Inc. - Zoom's stock dipped slightly by 0.04% to close at $78.60, with an intraday high of $80.27 and a low of $78.59; the stock's 52-week high is $92.80 [10][11] - The company reported third-quarter revenue of $1.23 billion and adjusted earnings of $1.52 per share, beating forecasts; enterprise revenue rose 6.1% year-over-year, ending the quarter with 4,363 large customers and generating $629.3 million in operating cash flow [11]